ARCHIVES

Amgen Claimed QOL Benefit Despite FDA Label Change.

This article is from The Cancer Letter archive.

Vol. 33 No. 19 | May 18, 2007

Download PDF Visit The Full Archive

Related Articles

Clinical Societies, Patient Groups Need New Alliance, Glick Proposes to ASCO

May 24, 1996

1.7% Cut Expected in NCI Budget Under Deficit Agreement

November 24, 1989

Moertel Criticizes Janssen Over Levamisole Price, Delivers Final Report On Intergroup Adjuvant Trial

June 12, 1992

Funding Opportunities: NCI Grant Supplements For Mammalian Models

October 22, 1999

In Congress: specer, Harkin Pan re-Introduction Of Research Trust Fund

March 21, 1997

Practice Management Giant US Oncology To Sell Practices Back to Physicians.

October 5, 2001